Myriad Genetics, Inc.

As of June 30, 2026, Myriad Genetics, Inc. carries a market capitalization of 470.54M, placing it among publicly traded companies globally. Its enterprise value stands at 553.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Myriad Genetics, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Myriad Genetics, Inc. has 95.60M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.65, and the price-to-book ratio stands at 1.77.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 553.96M versus a market cap of 470.54M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Myriad Genetics, Inc. maintains a current ratio of 2.21, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 69.27, indicating elevated leverage, while an interest coverage ratio of -2.95 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Myriad Genetics, Inc. posted a negative return on equity (ROE) of -32.54, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -17.11, reflecting losses generated across the asset base. The company generates approximately 261,487.77 in revenue per employee across its workforce of 2,700.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.48 indicates how many times Myriad Genetics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Myriad Genetics, Inc. recorded 700,240.00 in income tax expense. The company reported a pretax loss of -97.86M and -98.56M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Myriad Genetics, Inc.'s stock has declined approximately 26.45% over the past 52 weeks. The 50-day moving average sits at 3.28, while the 200-day moving average is 3.89.

Over the twelve months ended June 30, 2026, Myriad Genetics, Inc. generated 706.02M in revenue and converted that into -98.56M in net income, yielding earnings per share of -1.05. EBITDA reached -42.36M, while operating income came in at -79.21M.

As of June 30, 2026, Myriad Genetics, Inc. holds 100.83M in cash and equivalents against 184.25M in total debt, resulting in a net debt position of 4.81M. Total book value stands at 266.00M, with working capital of 138.56M providing operational flexibility.

Myriad Genetics, Inc. produced 6.74M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Myriad Genetics, Inc. posted a gross margin of 68.83, reflecting its pricing power and cost economics. The operating margin of -11.22 and net profit margin of -13.96 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.46, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -8.78, meaning Myriad Genetics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Myriad Genetics, Inc.'s most recent stock split took place on March 26, 2009 with a 1:2 split ratio.

As of June 30, 2026, Myriad Genetics, Inc. has an Altman Z-Score of -1.21, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.